Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

24.91 -0.25 (-0.99%)
Streaming Delayed Price Updated: 3:02 PM EST, Dec 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
News headline image
Nasdaq Rises More Than 300 Points; Crude Oil Moves Higher ↗
U.S. stocks extended gains toward the end of trading, with the Nasdaq Composite gaining around 3% on Tuesday. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
  
Via Benzinga
News headline image
Dow Climbs Over 500 Points as Upbeat Earnings Roll In ↗
The Dow Jones Industrial Average is up 510 points midday, as the newest string of earnings reports shows companies working through the current economic pressures. 
Via Talk Markets
News headline image
HC Wainwright Initiates Coverage On Upcoming Complement Franchise Company Apellis Pharmaceuticals ↗
 
Via Benzinga
News headline image
Dow Surges 500 Points; Johnson & Johnson Lowers Guidance ↗
U.S. stocks traded higher midway through trading, with the Dow Jones gaining around 500 points on Tuesday. 
Via Benzinga
News headline image
Expert Ratings for Apellis Pharmaceuticals ↗
Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
This Financial Services Stock Is Trading Higher By 50%, Here Are 40 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Applied Blockchain, Inc. (NASDAQ: APLD) jumped 50.1% to $1.5907 after the company reported a 200-megawatt five-year hosting contract with Marathon Digital Holdings and raised its Q4 revenue... 
Via Benzinga
News headline image
Why U.S. Stocks Are Trading Higher; Housing Starts Drop Further In June ↗
U.S. stocks traded higher this morning, with the Dow Jones gaining more than 350 points on Tuesday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Apellis Surges By Double Digits As FDA Mulls Its Eye-Disease Treatment ↗
The drug could be the first ever FDA-approved treatment for geographic atrophy. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: FDA Tentatively Approves Avadel's Narcolepsy Drug, European Approval Broadens AstraZeneca's Enhertu in Breast Cancer, Pharma Giants' Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals Stock Is Soaring ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher Tuesday after the company announced the U.S. Food and Drug Administration accepted and granted priority review designation for the... 
Via Benzinga
News headline image
Apellis Shares Climb As FDA Accepts Geographic Atrophy Candidate Submission Under Priority Review ↗
The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review designation for Apellis Pharmaceuticals’ (NASDAQ: APLS) New Drug Application (NDA) for the intravitreal... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Apellis Pharmaceuticals Stock Scores Relative Strength Rating Upgrade ↗
ApellisPharmaceuticals sees its Relative Strength Rating reach the elite 90-plus level. 
Via Investor's Business Daily
News headline image
Apellis Pharmaceuticals Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating ↗
Apellis Pharmaceuticals stock saw its Relative Strength (RS) Rating upgraded to 85 Friday, up from 79 a day earlier. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax's COVID-19 Shot, New Data On Moderna's Omicron Vaccine, DBV Tech's Encouraging Peanut Allergy Trial Data ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Apellis Begins Paitent Dosing In Late-Stage Study Of Rare Kidney Disease Candidate ↗
Apellis Pharmaceuticals (NASDAQ: APLS) has dosed first patient in the VALIANT Phase 3 clinical study of its drug candidate Pegcetacoplan for primary immune-complex membranoproliferative... 
Via Benzinga
News headline image
Expert Ratings for Apellis Pharmaceuticals ↗
Over the past 3 months, 7 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Goldman Sachs Maintains Buy Rating for Apellis Pharmaceuticals: Here's What You Need To Know ↗
Goldman Sachs has decided to maintain its Buy rating of Apellis Pharmaceuticals (NASDAQ:APLS) and lower its price target from $94.00 to $84.00. Shares of Apellis Pharmaceuticals are trading down 2.3%... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Apellis Pharmaceuticals's Earnings: A Preview ↗
Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Expert Ratings for Apellis Pharmaceuticals ↗
Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗
Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91. 
Via Investor's Business Daily
News headline image
The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the... 
Via Benzinga
News headline image
Why Apellis Pharmaceuticals Stock Is Falling After Hours ↗
Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million... 
Via Benzinga
News headline image
Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing ↗
If approved, this would be the company's second drug to hit the U.S. market. 
Via Investor's Business Daily
< Previous 1 2
...
13 14 15 16 17 18 19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.